Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

765
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
765
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

3.1K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
3.1K
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

813
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
813
Dialysis01:27

Dialysis

1.4K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.4K
Dialysis01:15

Dialysis

1.8K
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
1.8K
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

515
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periodontitis and early mortality among adults treated with hemodialysis: a multinational propensity-matched cohort study.

BMC nephrology·2017
Same author

Centre effects and peritoneal dialysis-related peritonitis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2017
Same author

Parental experiences and preferences as participants in pediatric research conducted in the emergency department.

CJEM·2017
Same author

Improving Nutrition Research in Nephrology: An Appetite for Change.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2017
Same author

Dietary interventions for adults with chronic kidney disease.

The Cochrane database of systematic reviews·2017
Same author

Assessment of Global Kidney Health Care Status.

JAMA·2017

Related Experiment Video

Updated: Feb 3, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.0K

Biocompatible dialysis fluids for peritoneal dialysis.

Htay Htay1, David W Johnson, Kathryn J Wiggins

  • 1Department of Renal Medicine, Singapore General Hospital, 20 College Street, Singapore, Singapore, 169856.

The Cochrane Database of Systematic Reviews
|October 27, 2018
PubMed
Summary

Biocompatible peritoneal dialysis (PD) solutions, including neutral pH, low glucose degradation product (GDP) solutions and icodextrin, show benefits in preserving residual renal function and fluid management. However, their effects on peritonitis and survival remain uncertain, requiring further research.

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.2K
Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion
06:23

Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion

Published on: May 23, 2025

2.3K

Related Experiment Videos

Last Updated: Feb 3, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.0K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.2K
Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion
06:23

Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion

Published on: May 23, 2025

2.3K

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Clinical Trials

Background:

  • Biocompatible peritoneal dialysis (PD) solutions, such as neutral pH, low glucose degradation product (GDP) formulations and icodextrin, have emerged as alternatives to standard PD solutions.
  • Previous studies suggested favorable patient outcomes with biocompatible PD solutions, but often with suboptimal study quality.
  • Recent randomized controlled trials (RCTs) provide updated evidence on the benefits and harms of these solutions.

Purpose of the Study:

  • To evaluate the benefits and harms of biocompatible PD solutions compared to standard PD solutions in patients undergoing PD.
  • To synthesize evidence from recent RCTs on neutral pH, low GDP PD solutions and icodextrin.

Main Methods:

  • Systematic review and meta-analysis of RCTs and quasi-RCTs involving adult and pediatric PD patients.
  • Inclusion of studies comparing neutral pH, low GDP PD solutions or icodextrin against conventional PD solutions.
  • Data extraction on study quality and outcomes, with random-effects modeling for effect estimation.

Main Results:

  • Neutral pH, low GDP PD solutions significantly improved residual renal function (RRF) preservation (high certainty evidence) and residual urine volume preservation (high certainty evidence).
  • Icodextrin use was associated with reduced fluid overload episodes and augmented peritoneal ultrafiltration (moderate certainty evidence).
  • Evidence regarding the effects of these solutions on peritonitis, hospitalization, technique failure, or patient survival remains uncertain due to low certainty or heterogeneity.

Conclusions:

  • Biocompatible PD solutions, particularly neutral pH, low GDP formulations, demonstrate a high certainty of preserving residual renal function and urine volume.
  • Icodextrin effectively increases peritoneal ultrafiltration and manages fluid overload.
  • Further high-quality RCTs are necessary to clarify the impact of biocompatible PD solutions on critical outcomes like peritonitis and patient survival.